Oncology · 1979
Total Therapy / combination treatment curing childhood ALL
Acute Lymphoblastic Leukemia (ALL)
In the mid-1950s, acute lymphoblastic leukemia in children was nearly uniformly fatal within months. Single agents, first aminopterin and then methotrexate, could induce temporary remissions, but relapse was the rule and median survival from diagnosis was measured in weeks to a few months. The disease did not behave like a localized tumor that could be excised; it required systemic treatment sustained over time, and no existing framework for doing that existed.
Donald Pinkel arrived at St. Jude Children's Research Hospital in Memphis in 1962 as its first medical director and began constructing what he called Total Therapy, a phased treatment program that combined induction chemotherapy to achieve remission with consolidation, maintenance, and, critically, direct treatment of the central nervous system. The CNS element was the key insight: the blood-brain barrier shielded leukemic lymphoblasts from most systemic agents, allowing residual cells to persist and seed relapse even after apparent complete remission. Pinkel's team addressed this with cranial irradiation and intrathecal methotrexate delivered directly into the cerebrospinal fluid.
Sequential versions of Total Therapy, numbered I through VIII through the 1960s and 1970s, each refined the drug combinations, doses, and CNS treatment approach. The multidrug backbone typically included vincristine, prednisone, asparaginase, and methotrexate in various sequences. By the late 1970s, roughly half of treated children were alive and disease-free at five years. Pinkel summarized the program's results in his 1979 David Karnofsky Lecture, published in Cancer, presenting the most complete account of how iterative protocol revision had transformed the disease from fatal to potentially curable.
The protocols attracted scrutiny as long-term survivors accumulated. Cranial irradiation, while effective at preventing CNS relapse, produced measurable neurocognitive deficits, including reductions in IQ scores, memory problems, and white matter changes on imaging. Subsequent investigators replaced prophylactic cranial radiation with intensified intrathecal chemotherapy regimens in most patients, preserving CNS control while reducing late neurological toxicity. That transition, completed at most centers through the 1980s and 1990s, required its own set of trials and refinements.
Current five-year survival for childhood ALL exceeds 90 percent in high-income countries, placing it among the most curable cancers in oncology. That figure reflects decades of protocol refinement built on the Total Therapy structure, including risk stratification by cytogenetics, intensification for high-risk subgroups, and targeted therapy for Philadelphia-chromosome-positive disease. The foundational principle that curing leukemia requires sustained, multi-agent, CNS-inclusive treatment came directly from Pinkel's work in Memphis.
Key People
- Donald Pinkel — St. Jude oncologist who designed and directed the Total Therapy protocols
- Joseph Simone — St. Jude pediatric oncologist who contributed to later Total Therapy iterations
- Emil Frei III — Oncologist whose early combination chemotherapy trials at NCI preceded Total Therapy
Pinkel D. Cancer 1979;43:1128-1137 (Ninth Annual David Karnofsky Lecture; Total Therapy)
Related landmarks
- 1976 · Harald zur Hausen hypothesis linking HPV to cervical cancer (Oncology)
- 1975 · Allogeneic bone marrow (hematopoietic stem cell) transplantation as curative therapy (Thomas) (Oncology)
- 1971 · Health Insurance Plan (HIP) of Greater New York mammography trial (Oncology)
- 1970 · MOPP combination chemotherapy for Hodgkin's disease (Oncology)